Status:
COMPLETED
Use, Effects and Side-effects of Second-generation Antipsychotics in a Naturalistic Setting
Lead Sponsor:
University of Bergen
Conditions:
Psychotic Disorders
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Despite different pharmacological properties, the scientific evidence is inconclusive regarding which of the first-line second generation antipsychotics (SGAs) should be preferred for the individual p...
Eligibility Criteria
Inclusion
- Psychosis
- Must be able to use oral antipsychotic drugs
Exclusion
- Mania
- Unable to cooperate with the assessments
- Unable to understand Norwegian language
- Candidates for electroconvulsive therapy
- Use of Clozapine at admittance
Key Trial Info
Start Date :
February 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2010
Estimated Enrollment :
226 Patients enrolled
Trial Details
Trial ID
NCT00932529
Start Date
February 1 2003
End Date
January 1 2010
Last Update
May 25 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Haukeland University Hospital, Division of Psychiatry
Bergen, Sandviken, Norway, N-5035